Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Jochen K. Lennerz"'
Autor:
Colin D. Weekes, James C. Cusack, Christine E. Eyler, Lipika Goyal, Jochen K. Lennerz, Emily E. Van Seventer, Jill N. Allen, Jennifer Y. Wo, Peter J. Ulintz, Andrew X. Zhu, Hui Zheng, Susan G.R. McDuff, Theodore S. Hong, Daniel Kim, David P. Ryan, Mehlika Hazar-Rethinam, Jeffrey W. Clark, Ryan B. Corcoran, Isobel J Fetter, Brandon Nadres, Lawrence S. Blaszkowsky, Aparna Raj Parikh, Karin M. Hardiman
Publikováno v:
JCO Precis Oncol
PURPOSE This study was designed to assess the ability of perioperative circulating tumor DNA (ctDNA) to predict surgical outcome and recurrence following neoadjuvant chemoradiation for locally advanced rectal cancer (LARC). MATERIALS AND METHODS Twen
Autor:
Ibiayi Dagogo-Jack, Russell W. Madison, Jochen K. Lennerz, Kuei-Ting Chen, Julia F. Hopkins, Alexa B. Schrock, Lauren L. Ritterhouse, Ashley Lester, Keith A. Wharton Jr, Mari Mino-Kenudson, Natalie Danziger, Yin P. Hung, Douglas A. Mata, Jeffrey S. Ross
Publikováno v:
JCO Precision Oncology.
PURPOSE Mesothelioma is an aggressive malignancy with heterogeneous outcomes that are partly driven by the differential efficacy of existing therapies across histologic types and sites of origin. Large-scale molecular analysis of mesothelioma and its
Autor:
Eric B. Haura, A. John Iafrate, Alexander Drilon, Alexander I. Spira, Shivaani Kummar, Sai-Hong Ignatius Ou, Martin S. Taylor, Long P. Le, Viola W. Zhu, Jochen K. Lennerz, Mari Mino-Kenudson, Ryma Benayed, Maria E. Arcila, Theresa A. Boyle, Robert C. Doebele, Anna F. Farago, Alice T. Shaw, Nora Horick, Dara L. Aisner
Publikováno v:
JCO Precision Oncology. :1-12
Purpose Gene rearrangements that involve NTRK1/2/3 can generate fusion oncoproteins that contain the kinase domains of TRKA/B/C, respectively. These fusions are rare in non–small-cell lung cancer (NSCLC), with frequency previously estimated to be <
Autor:
Valentina Nardi, Miguel Rivera, Hayley Robinson, Florian J. Fintelmann, Jennifer S. Temel, Zofia Piotrowska, Mari Mino-Kenudson, Subba R. Digumarthy, Inga T. Lennes, A. John Iafrate, Jessica J. Lin, Jochen K. Lennerz, Dora Dias-Santagata, Meghan J. Mooradian, Christopher G Azzolli, Julie M. Batten, Lecia V. Sequist, Justin F. Gainor, Ginger Y. Jiang, Jo-Anne O. Shepard, Alice T. Shaw, Long P. Le, Martha B. Pitman, Ibiayi Dagogo-Jack, Anna F. Farago, Vania Nosé, Rebecca S. Heist
Publikováno v:
JCO Precision Oncology. :1-13
Purpose Targeted therapy is the cornerstone of treatment of advanced EGFR-mutant non–small-cell lung cancer (NSCLC). Next-generation sequencing (NGS), the preferred method for genotyping, typically requires several weeks. Here, we assessed workflow
Publikováno v:
Journal of Clinical Oncology. 38:e14124-e14124
e14124 Background: VALID Act is a bipartisan draft legislation proposing to ensure the quality and safety of diagnostic tests through direct FDA oversight. Currently, FDA exercises enforcement discretion and exempts from premarket review tests that a
Autor:
Jochen K. Lennerz, Jessica J. Lin, Theodore O. Johnson, Charlotte E. Lee, Justin F. Gainor, Beow Y. Yeap, Harper Hubbeling, Ibiayi Dagogo-Jack, Alice T. Shaw
Publikováno v:
Journal of Clinical Oncology. 38:9611-9611
9611 Background: Lorlatinib is a potent, brain-penetrant ROS1/ALK tyrosine kinase inhibitor (TKI), which has demonstrated efficacy in advanced ROS1 fusion-positive (ROS1+) non-small cell lung cancer (NSCLC), including in patients (pts) previously tre
Autor:
Enrique Dominguez Meneses, Emily Chin, A. John Iafrate, Marguerite Rooney, Alice T. Shaw, Lev Lipkin, Long P. Le, Jochen K. Lennerz, Michael G Zomnir
Publikováno v:
Journal of Clinical Oncology. 37:3079-3079
3079 Background: ALK tyrosine kinase inhibitors (TKIs) are effective in treating advanced anaplastic lymphoma kinase (ALK) fusion-positive non-small-cell lung cancers (NSCLC), and specific ALK variants are associated with the development of resistanc
Autor:
Lipika Goyal, Andrew X. Zhu, David T. Ting, Jochen K. Lennerz, Vikram Deshpande, Nabeel Bardeesy, Abhijit Chougule
Publikováno v:
Journal of Clinical Oncology. 37:281-281
281 Background: Fibroblast growth factor receptor (FGFR) inhibitors show promising activity in patients with intrahepatic CCA harboring FGFR2 fusions, but these alterations have a modest frequency of 15-20%. FGFR mRNA expression has shown preliminary
Autor:
Pablo Martinez, Bruce E. Johnson, Tom C. Nguyen, Christine A. Lydon, Alice T. Shaw, A. John Iafrate, Jochen K. Lennerz, Chiara Ambrogio, Beow Y. Yeap, Mark M. Awad, Ibiayi Dagogo-Jack
Publikováno v:
Journal of Clinical Oncology. 36:9045-9045
9045Background: BRAF mutations (muts) occur in 2-4% of NSCLC. Recent work suggests that BRAF muts may be grouped into 3 classes: 1) V600 muts that signal as monomers, 2) activating non-V600 muts th...
Autor:
Jochen K. Lennerz, Jessica J. Lin, Alice T. Shaw, Justin F. Gainor, Lorin A. Ferris, Satoshi Yoda, Beow Y. Yeap, Ibiayi Dagogo-Jack
Publikováno v:
Journal of Clinical Oncology. 36:9093-9093
9093Background: Alectinib was recently approved for first-line treatment of advanced ALK+ NSCLC based on the ALEX trial, which demonstrated improved PFS with first-line alectinib compared to crizot...